Sign In
Buy CORT
$79.85
+0.140 (+0.176%)
At Close: Jun 23, 2026
Corcept Therapeutics (CORT) Meets Q4 Earnings Estimates
11:15pm, Thursday, 20'th Feb 2020
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -0.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Corcept: 4Q Earnings Snapshot
10:06pm, Thursday, 20'th Feb 2020
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported fourth-quarter profit of $29.4 million. On a per-share basis, the Menlo Park, California-based company said it had net i
Corcept: 4Q Earnings Snapshot
10:05pm, Thursday, 20'th Feb 2020
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported fourth-quarter profit of $29.4 million.
On a per-share basis, the Menlo Park, California-based company said it had net i
Corcept Therapeutics Q4 EPS $0.24 Misses $0.25 Estimate, Sales $87.9M Beat $87.67M Estimate
09:19pm, Thursday, 20'th Feb 2020Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update
09:05pm, Thursday, 20'th Feb 2020
MENLO PARK, Calif., Feb. 20, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
